Clinical significance of prostate 18F-labelled fluorodeoxyglucose uptake on positron emission tomography/computed tomography: A five-year review

Table 3 Characteristics of patients in whom elevated prostatic ¹⁸F-labelled fluorodeoxyglucose uptake was investigated

Age (yr)	18F-FDG PET/CT indication	Prostate SUVmax	PSA (ng/mL)	Urology referral made	Urology outcome
68	Adrenal nodule	10.4	3	Yes	MRI - no suspicious foci
77	Lung nodule	4.5	2.78	Yes	Biopsy - high-grade PIN
67	Non-Hodgkin lymphoma	4.5	5.5	Yes	MRI - suspicious foci
					Biopsy - benign
68	Colorectal cancer	5.9	3.04	Yes	PSA monitoring
58	Colorectal cancer	7.6	1.38	Yes	PSA monitoring
64	Non-Hodgkin lymphoma	5.4	1.84	Yes	PSA monitoring
58	Non-Hodgkin lymphoma	19.9	7.44	Yes	PSA monitoring
81	Cholangiocarcinoma	10.3	18	Yes	Lost to follow up
75	Hepatic metastases (colorectal primary)	8	-	Yes	Lost to follow up
61	Colorectal cancer	14	1.47	No - PSA normal
55	Paraneoplastic syndrome	4.8	0.62	No - PSA normal
61	Non-Hodgkin lymphoma	5.8	2.85	No - PSA normal
68	Gastrointestinal stromal tumour	13.2	1.48	No - PSA normal
71	Hepatic metastases (colorectal primary)	9.2	4.9	No - palliative care
87	Oesophageal cancer	5.3	11.86	No - palliative care
82	Colorectal cancer	15.4	3.85	No - palliative care
35	Hodgkin lymphoma	11.8	3.04	No - suspected prostatitis
71	Oesophageal cancer	7.3	4.58	No - likely urethral uptake

SUV: Standardised uptake value; PSA: Prostate specific antigen; PIN: Prostatic intraepithelial neoplasia.